An update on ripasudil for the treatment of glaucoma and ocular hypertension.
-
V. Testa [2] [1] ; L. Ferro Desideri [2] [1] ; P. Della Giustina [2] [1] ; C.E. Traverso [2] [1] ; M. Iester [2] [1]
-
[1] University of Genoa
University of Genoa
Genoa, Italia
-
[2] University Eye Clinic of Genoa, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
-
- Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 56, Nº. 9, 2020, págs. 599-608
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Ripasudil (K-115) is a novel Rho-associated protein kinase (ROCK) inhibitor. The Rho-ROCK pathway regulates key downstream effectors involved in many cellular functions, in particular in the actin cytoskeleton activity. The clinical effects of ripasudil expected on the eye include an intraocular pressure-lowering effect and a wound-healing activity on corneal endothelial cells, but many other functions are currently under investigation. To date, ripasudil has been approved in Japan (2014) for the treatment of glaucoma and ocular hypertension, and several clinical trials are currently investigating its role in the treatment of Fuchs' corneal dystrophy. In this review, we will discuss its pharmacokinetics, pharmacodynamics and clinical efficacy, focusing also on its safety and tolerability profile.
